|
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
BEFREE |
The aim of this study was the evaluation of serum levels of osteopontin (OPN) and tumor endogenous angiogenic factors such as vascular-endothelial growth factor (VEGF), vascular-endothelial growth factor receptor 2 (VEGF R2), endostatin, angiostatin and thrombospondin 1, in prostate cancer (PC) patients.
|
30178447 |
2019 |
|
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
BEFREE |
A model combining two cancer-related glycoproteins (THBS1 and CTSD) and %fPSA can improve PCa diagnosis and may reduce the number of unnecessary prostate biopsies because of its improved specificity for PCa when compared to %fPSA alone.
|
30216634 |
2019 |
|
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
BEFREE |
Taken together, we elucidate a new critical pathway, consisting of CREB/EZH2/TSP1, underlying ADT-enhanced NED and angiogenesis during prostate cancer progression.
|
30287808 |
2018 |
|
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
BEFREE |
Conclusively, the use of CTSD and THBS1 together with commonly used parameters for PCa diagnosis such as %fPSA and age has the potential to improve the diagnosis of PCa.
|
28767721 |
2017 |
|
Malignant neoplasm of prostate
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Therefore, quercetin could increase TSP-1 expression to inhibit angiogenesis resulting in antagonizing prostate cancer PC-3 cell and xenograft tumor growth.
|
26676551 |
2016 |
|
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
BEFREE |
Genome-wide analysis in the human prostate cancer cell line DU-145 identified primary downregulated targets of DZ-50, including genes involved in focal adhesion integrity (fibronectin, integrin-α6 and talin), tight junction formation (claudin-11) as well as insulin growth factor binding protein 3 (IGFBP-3) and the angiogenesis modulator thrombospondin 1 (TSP-1).
|
24497940 |
2014 |
|
Malignant neoplasm of prostate
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Similarly, gene-gene interaction of VEGF and TSP1 polymorphisms increased risk of prostate cancer in additive manner (OR = 6.00, P = 0.03), although the TSP1 polymorphism itself was not associated with the risk.
|
17917789 |
2009 |
|
Malignant neoplasm of prostate
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
TSP1 protein levels are increased upon beta(1C) expression in prostate cancer cells as well as in beta(1)-null GD25 cells.
|
19549894 |
2009 |
|
Malignant neoplasm of prostate
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
No association was observed between any of the TSP1 genotypes and PCa risk or severity; however, subjects carrying one copy of the MMP9 T allele exhibited threefold higher risk of developing PCa (OR = 2.86; P = 0.004).
|
17175378 |
2007 |
|
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
BEFREE |
Overall, these results suggest that the high in situ TSP1 exposure triggered by androgen deprivation in patients with prostate cancer could lead to early tumor resistance.
|
15665307 |
2005 |
|
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
RGD |
The present study was therefore designed to evaluate the expression of thrombospondin 1 and 2 (TSP-1, TSP-2), TSP receptors CD36 and CD47, and matrix-metalloproteases 2 and 9 (MMP-, MMP-9) in a rat prostate cancer model.
|
16076702 |
2005 |
|
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
BEFREE |
These results suggest that TSP-1 may be a potentially useful gene for prostate cancer gene therapy.
|
11228532 |
2000 |